OKYO Pharma Secures U.S. Patent for OK-101's Dry Eye Disease Treatment

LONDON and NEW YORK, Aug. 27, 2024 -- OKYO Pharma Limited (NASDAQ: OKYO), a biopharmaceutical company at the clinical stage, has announced the granting of a pivotal U.S. Patent No. 12,053,501 issued on August 6th. This patent, titled "Methods for Treating Symptoms of Dry Eye Disease," pertains to the use of OK-101 in alleviating symptoms such as irritation, burning eyes, and blurred vision in patients suffering from dry eye disease (DED). The issuance of this patent significantly bolsters the company's intellectual property in this sector.

Dr. Gary S. Jacob, CEO of OKYO, expressed his enthusiasm about the patent issuance, emphasizing that it highlights the innovative capabilities of OK-101 in treating DED. He noted that this milestone not only strengthens the company’s IP portfolio but also enhances OKYO Pharma's position in addressing substantial unmet medical needs. Dr. Jacob also mentioned that the company remains committed to discovering partnerships and collaborations to expedite the development and commercialization of its drug candidates.

OK-101, a lipid-conjugated chemerin peptide agonist, targets the ChemR23 G-protein coupled receptor typically present on immune cells in the eye responsible for the inflammatory response. This drug was developed using membrane-anchored-peptide technology, resulting in a novel, long-lasting candidate for treating dry eye disease. OK-101 has demonstrated anti-inflammatory and pain-reducing effects in mouse models of DED and neuropathic corneal pain (NCP). The inclusion of a lipid anchor in OK-101 enhances its residence time in the ocular environment, thereby preventing washout. Recently, OK-101 exhibited statistical significance across multiple endpoints in a Phase 2, multi-center, double-blind, placebo-controlled trial.

OKYO Pharma Limited, listed on the NASDAQ Capital Market, focuses on developing innovative therapies for treating both DED and NCP. The company has completed a Phase 2 trial for OK-101 targeting dry eye disease and is preparing for another Phase 2 trial aimed at treating NCP in patients suffering from this challenging condition. 

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!